Circulating TNF-RII, IP-10 and HGF are associated with severity of COVID-19 in oncologic patients

The COVID-19 patients showed hyperinflammatory response depending on the severity of the disease but little have been reported about this response in oncologic patients that also were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sixty-five circulating cytokines/che...

Descripción completa

Detalles Bibliográficos
Autores: Carrillo-García, Jaime, Lacerenza, Serena, Hindi, Nadia, Moura, David S., Marquina, Gloria, Parra Corral, Daniel, Olalla, Jennifer, Cano Cano, Juana María, Hoyos, Sergio, Renshaw, Marta, Mondaza-Hernández, José L., Di Lernia, Davide, Casado, Antonio, Manzano, Arantxa, Gutiérrez, Antonio, Martín-Broto, Javier
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/360014
Acceso en línea:http://hdl.handle.net/10261/360014
https://api.elsevier.com/content/abstract/scopus_id/85185338942
Access Level:acceso abierto
Palabra clave:TNF-RII
COVID-19
HGF
IP-10
Oncologic patients
Descripción
Sumario:The COVID-19 patients showed hyperinflammatory response depending on the severity of the disease but little have been reported about this response in oncologic patients that also were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sixty-five circulating cytokines/chemokines were quantified in 15 oncologic patients, just after SARS-CoV-2 infection and fourteen days later, and their levels were compared in patients who required hospitalisation by COVID-19 versus non-hospitalised patients. A higher median age of 72 years (range 61-83) in oncologic patients after SARS-CoV-2 infection was associated with hospitalisation requirement by COVID-19 versus a median age of 49 years (20-75) observed in the non-hospitalised oncologic patients (p = 0.008). Moreover, oncologic patients at metastatic stage or with lung cancer were significantly associated with hospitalisation by COVID-19 (p = 0.044). None of these hospitalised patients required ICU treatment. Higher basal levels of tumour necrosis factor receptor II (TNF-RII), interferon-γ (IFNγ)-induced protein 10 (IP-10) and hepatocyte growth factor (HGF) in plasma were significantly observed in oncologic patients who required hospitalisation by COVID-19. Higher TNF-RII, IP-10 and HGF levels after the SARS-CoV-2 infection in oncologic patients could be used as biomarkers of COVID-19 severity associated with hospitalisation requirements.

Similares en LA Referencia